Pictet Asset Management (UK)’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Pictet Asset Management (UK)’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-333,400	Closed	-$3.02M	–	892
2013 Q4	$3.02M	Sell	333,400 -132,800	-28%	-$959K	0.02%	648
2013 Q3	$2.94M	Sell	466,200 -222,300	-32%	-$1.41M	0.02%	652
2013 Q2	$4.7M	Buy	+688,500	New	+$4.8M	0.03%	502

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Pictet Asset Management (UK)'s CADX Position: Q1 2014 in Review

Pictet Asset Management (UK) sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 333,400 shares — an estimated $3.02M sold.

Pictet Asset Management (UK) first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $4.7M in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

Pictet Asset Management (UK) reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
Pictet Asset Management (UK) sold 333,400 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $3.02M.
Pictet Asset Management (UK) first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
Pictet Asset Management (UK)'s CADENCE PHARMACEUTICALS, INC COM STK position peaked at $4.7M in Q2 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Pictet Asset Management (UK)'s 13F filing for Q1 2014, filed 14 May 2014.